Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Gastric Cancer


Tsutomu Hayashi


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


T. Hayashi1, T. Yoshikawa1, K. Sakamaki2, K. Nishikawa3, K. Fujitani4, K. Tanabe5, Y. Ito6, T. Matsui7, A. Miki8, T. Fukunaga9, H. Nemoto10, Y. Kimura11, N. Hirabayashi12

Author affiliations

  • 1 Gastric Surgery, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Graduate School Of Medicine, Tokyo university, Tokyo/JP
  • 3 Gastrointestinal Surgery, Natinal Hospital Organization Osaka National Hospital, Osaka/JP
  • 4 Gastrointestinal Surgery, Osaka General Medical Center, Osaka/JP
  • 5 Gastroenterological And Transplant Surgery, Hiroshima University, Hiroshima/JP
  • 6 Gastrointestinal Surgery, Aichi Cancer Center Hospital, Nagoya/JP
  • 7 Surgery, Aichi Cacner Center Aichi Hospital, Okazaki/JP
  • 8 Surgery, Kobe City Medical Center General Hospital, Kobe/JP
  • 9 Gastrointestinal Surgery, St Marianna University School of Medicine, Kawasaki/JP
  • 10 Surgery, Showa University Fujigaoka Hospital, Yokohama/JP
  • 11 Gastrointestinal Surgery, Sakai City Medical Center, Sakai/JP
  • 12 Surgery, Hiroshima City Asa Citizens Hospital, Asa/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1402


Neoadjuvant chemotherapy is promising to improve the survival of locally advanced gastric cancer. However, optimal regimen and duration of treatment have not been established. We previously reported the primary results of COMPASS-D trial (ASCO-GI 2019). Herein, we report the results of subgroup analyses of efficacy by baseline disease characteristics and demographics.


Patients with M0 and either T4 or T3 in case of junctional cancer or schirrhous type received 2 or 4 courses of cisplatin (60 mg/m2 at day 8) / S-1 (80 mg/m2 for 21 days with 1 week rest) or docetaxel (40 mg/m2 at day 1) / cisplatin (60 mg/m2 at day 1) / S-1 (80 mg/m2 for 14 days with 2 weeks rest) as neoadjuvant chemotherapy. Then, patients underwent D2 gastrectomy and adjuvant S-1 chemotherapy for 1 year. The primary endpoint was 3-year overall survival. Subgroup analysis was performed in each regimen (CS vs DCS) and duration (2 vs 4 courses), stratified by age, gender, esophageal invasion, macroscopic type, histological type, cT, and cN.


Between Oct 2011 and Sep 2014, 132 patients were assigned to CS (n = 66; 33 in 2-courses and 33 in 4-courses) and DCS (n = 66; 33 in 2-courses and 33 in 4-courses). The 3-year OS was 58.1% in 2-courses CS, 58.1% in 4-courses CS, 48.5% in 2-courses DCS, and 71.9% in 4-courses DCS. Subgroup analyses were summarized in the table.Table:


SubgroupHR of 4-sourses (95%CI)HR of DCS (95%CI)
Overall0.77 (0.43-1.22)0.80 (0.48-1.34)
Age < 70 y.o.0.82 (0.45-1.52)0.88 (0.48-1.62)
Age = > 70 y.o.0.49 (0.17-1.39)0.68 (0.26-1.76)
Male0.53 (0.27-1.05)0.81 (0.42-1.54)
Female1.22 (0.51-2.90)0.79 (0.33-1.87)
Esophageal invasion-0.72 (0.40-1.31)0.71 (0.39-1.27)
Esophageal invasion+0.73 (0.24-2.17)1.06 (0.36-3.16)
Schirrhous or large Type30.47 (0.22-1.00)0.82 (0.41-1.63)
Non schirrous or large Type30.74 (0.23-2.41)0.50 (0.13-1.87)
Differentiated0.37 (0.08-1.66)0.38 (0.09-1.71)
Undiffirentiated0.66 (0.32-1.36)1.24 (0.63-2.43)
cT3 or T4a0.66 (0.38-1.17)0.76 (0.44-1.32)
cT4bN/A2.33 (0.26-21.4)
cN00.77 (0.32-1.86)0.74 (0.31-1.80)
cN + 0.66 (0.34-1.27)0.87 (0.46-1.66)


The DCS regimen and duration 4-courses showed a beneficial tendency as a neoadjuvant setting regardless of disease characteristics and demographics. The 4-courses DCS is widely applicable to future phase III study to confirm of neoadjuvant chemotherapy for locally advanced gastric cancer.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


The Nongovermental Organization, Kanagawa Standard Anti-cancer Therapy Support System.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.